Home » Topics » Pharmaceuticals » Postmarket Safety

April 2, 2020
Novartis Scraps $1 Billion Sandoz Sale to Aurobindo
Sandoz will continue to operate its oral solids and dermatology business as part of its U.S. business.
April 1, 2020
FDA Calls for Removal of All Ranitidine Products
In a reversal for the agency, the FDA called for the immediate withdrawal of all ranitidine products from the U.S. market due to N-Nitrosodimethylamine (NDMA) contamination.
April 1, 2020
FDA Calls for Withdrawal of All Ranitidine Products
Ranitidine products will not be available for new or existing prescription use in the U.S.

March 17, 2020
EMA Questions Safety of Ifosfamide-Containing Cancer Drugs
March 12, 2020
FDA Requires Boxed Warning on Singulair
March 11, 2020
Online Pharmacy Urges FDA to Pull Metformin Products with High NDMA Levels
March 3, 2020
Online Pharmacy Urges FDA to Pull Metformin Products With High NDMA Levels
February 28, 2020
FDA Publishes Details on Gene-Drug Interactions

February 24, 2020
Eisai Withdraws Belviq Over Cancer Concerns
February 20, 2020
FDA Publishes Details on Gene-Drug Interactions
February 6, 2020
FDA Calls for Voluntary Withdrawal of Injectable Bacitracin
November 15, 2019
GAO Flags How a REMS May Slow Generics
November 1, 2019
ICER Questions Cost-Effectiveness of Novo Nordisk’s Diabetes Drug Rybelsus

Products

Events